e-Therapeutics plc is a United Kingdom-based drug discovery and development company. The Company's discovery platform is based on the network of pharmacology and chemical biology. The Company operates in the business segment of drug discovery and development. The Company applies its platform to the discovery of new drug candidates. The therapeutic focus of the Company's discovery activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and antivirals. The Company generates a range of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule antiTNFα; ETS2400, in Hedgehog pathway inhibition, and ETS5200, which delivers a range of spectrum antivirals. The Company has completed a Phase IIb study of a drug candidate for depressive disorder, ETS6103, as well as Phase I clinical trials in cancer for ETS2101.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: LON:ETX
- CUSIP: N/A
- Web: www.etherapeutics.co.uk/
- Market Cap: £32.55 million
- Outstanding Shares: 268,426,000
- 50 Day Moving Avg: GBX 8.78
- 200 Day Moving Avg: GBX 8.45
- 52 Week Range: GBX 6 - GBX 13.90
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.000
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: GBX 0.06 per share
- Price / Book: 2.02
- EBIDTA: ($12,870,000.00)
- Return on Equity: -55.85%
- Return on Assets: -50.35%
- Average Volume: 2.18 million shs.
Frequently Asked Questions for e-Therapeutics plc (LON:ETX)
What is e-Therapeutics plc's stock symbol?
e-Therapeutics plc trades on the London Stock Exchange (LON) under the ticker symbol "ETX."
When will e-Therapeutics plc make its next earnings announcement?
Who are some of e-Therapeutics plc's key competitors?
Some companies that are related to e-Therapeutics plc include Palatin Technologies (PTN), Sunesis Pharmaceuticals (SNSS), Abzena PLC (ABZA), OvaScience (OVAS), CASI Pharmaceuticals (CASI), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Eiger BioPharmaceuticals (EIGR), ReNeuron Group Plc (RENE), Regulus Therapeutics (RGLS), Fibrocell Science (FCSC), Prima BioMed Ltd (PBMD), Caladrius Biosciences (CLBS), Senomyx (SNMX), Burcon NutraScience Corp (BUR), Cleveland BioLabs (CBLI), Bio-Path Holdings (BPTH) and Scancell Holdings Plc (SCLP).
Who are e-Therapeutics plc's key executives?
e-Therapeutics plc's management team includes the folowing people:
- Iain Gladstone Ross, Executive Chairman of the Board
- Raymond John Barlow, Chief Executive Officer, Director
- Steven Medlicott, Chief Financial Officer, Interim Chief Operating Officer, Director
- Trevor M. Jones Ph.D., CBE, Non-Executive Director
- Bradley Richard Hoy, Independent Non-Executive Director
How do I buy e-Therapeutics plc stock?
Shares of e-Therapeutics plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is e-Therapeutics plc's stock price today?
MarketBeat Community Rating for e-Therapeutics plc (LON ETX)MarketBeat's community ratings are surveys of what our community members think about e-Therapeutics plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of e-Therapeutics plc stock can currently be purchased for approximately GBX 12.13.
Consensus Ratings for e-Therapeutics plc (LON:ETX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for e-Therapeutics plc (LON:ETX)
(Data available from 6/28/2015 forward)
|8/17/2015||N+1 Singer||Reiterated Rating||Corporate|
Earnings History for e-Therapeutics plc (LON:ETX)Earnings History by Quarter for e-Therapeutics plc (LON ETX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for e-Therapeutics plc (LON:ETX)
Current Year EPS Consensus Estimate: $-3.600 EPS
Dividend History for e-Therapeutics plc (LON:ETX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for e-Therapeutics plc (LON:ETX)Insider Trades by Quarter for e-Therapeutics plc (LON:ETX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/1/2017||Steve Medlicott||Insider||Buy||1,000,000||GBX 6||£60,000|
|5/12/2017||Trevor Mervyn Jones||Insider||Buy||59,400||GBX 8||£4,752|
|1/3/2017||Trevor Mervyn Jones||Insider||Buy||36,917||GBX 7||£2,584.19|
|1/21/2015||Steve Medlicott||Insider||Buy||150,000||GBX 25.25||£37,875|
Headline Trends for e-Therapeutics plc (LON:ETX)
Latest Headlines for e-Therapeutics plc (LON:ETX)
e-Therapeutics plc (ETX) Chart for Wednesday, June, 28, 2017